Last updated on June 2018

Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)


Brief description of study

The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.

Clinical Study Identifier: NCT03413852

Find a site near you

Start Over

CHU Bic tre

Le Kremlin-Bicêtre, France
9.6miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.